Fusion Antibodies plc
Research Fusion Antibodies plc (FAB.L) on Bullrun: market cap GBX 1.41B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFAB.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 1.41B
- Financial periodFY2026
- RevenueGBP 2.11M
- Revenue growth7.4%
- Net income-GBP 1.15M
- Free cash flow-GBP 1.17M
- Gross margin58.3%
Valuation Snapshot
latest market cap is GBX 1.41B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | GBP 2.11M | -GBP 1.15M | -GBP 1.17M | 58.3% | n/a | GBP 1.04M | GBP 331.00K | GBP 1.62M |
| FY2025 | GBP 1.97M | -GBP 1.63M | -GBP 1.37M | 21.9% | -0.02 | GBP 359.00K | GBP 20.00K | GBP 756.00K |
| FY2024 | GBP 1.14M | -GBP 2.23M | -GBP 1.77M | -4.0% | -0.04 | GBP 1.20M | GBP 43.00K | GBP 1.79M |
| FY2023 | GBP 2.90M | -GBP 2.60M | -GBP 1.87M | 19.8% | -0.1 | GBP 195.00K | GBP 75.00K | GBP 1.12M |
| FY2022 | n/a | n/a | n/a | n/a | -0.05 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 1.41B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Fusion Antibodies plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fusion Antibodies plc's market cap?
Fusion Antibodies plc's market capitalization is GBX 1.41B.
What does Fusion Antibodies plc do?
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cell line development and cGMP scale up services.